{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:43:41Z","timestamp":1761745421692},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00108-021-00996-0","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T13:02:52Z","timestamp":1615554172000},"page":"496-504","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Asymptomatischer prim\u00e4rer Hyperparathyreoidismus"],"prefix":"10.1007","volume":"62","author":[{"given":"Katja","family":"Gollisch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heide","family":"Siggelkow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"996_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0140-6736(09)60507-9","volume":"374","author":"WD Fraser","year":"2009","unstructured":"Fraser\u00a0WD (2009) Hyperparathyroidism. Lancet 374:145\u2013158","journal-title":"Lancet"},{"key":"996_CR2","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1210\/jc.2015-3908","volume":"101","author":"BL Clarke","year":"2016","unstructured":"Clarke\u00a0BL, Brown\u00a0EM, Collins\u00a0MT, Juppner\u00a0H, Lakatos\u00a0P, Levine\u00a0MA, Mannstadt\u00a0MM, Bilezikian\u00a0JP, Romanischen\u00a0AF, Thakker\u00a0RV (2016) Epidemiology and diagnosis of hypoparathyroidism. J\u00a0Clin Endocrinol Metab 101:2284\u20132299","journal-title":"J Clin Endocrinol Metab"},{"key":"996_CR3","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1210\/jc.2012-4022","volume":"98","author":"MW Yeh","year":"2013","unstructured":"Yeh\u00a0MW, Ituarte\u00a0PH, Zhou\u00a0HC, Nishimoto\u00a0S, Liu\u00a0IL, Harari\u00a0A, Haigh\u00a0PI, Adams\u00a0AL (2013) Incidence and prevalence of primary hyperparathyroidism in a\u00a0racially mixed population. J\u00a0Clin Endocrinol Metab 98:1122\u20131129","journal-title":"J Clin Endocrinol Metab"},{"key":"996_CR4","first-page":"81","volume":"180","author":"S Tezelman","year":"1995","unstructured":"Tezelman\u00a0S, Rodriguez\u00a0JM, Shen\u00a0W, Siperstein\u00a0AE, Duh\u00a0QY, Clark\u00a0OH (1995) Primary hyperparathyroidism in patients who have received radiation therapy and in patients who have not received radiation therapy. J\u00a0Am Coll Surg 180:81\u201387","journal-title":"J Am Coll Surg"},{"key":"996_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s00268-009-0294-x","volume":"34","author":"G Cavallaro","year":"2010","unstructured":"Cavallaro\u00a0G, Cucina\u00a0A, Coluccia\u00a0P, Petramala\u00a0L, Cotesta\u00a0D, Polistena\u00a0A, Zinnamosca\u00a0L, Letizia\u00a0C, Rosato\u00a0L, Cavallaro\u00a0A, De Toma\u00a0G (2010) Role of growth factors on human parathyroid adenoma cell proliferation. World J Surg 34:48\u201354","journal-title":"World J Surg"},{"key":"996_CR6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.beem.2010.01.003","volume":"24","author":"JM Sharretts","year":"2010","unstructured":"Sharretts\u00a0JM, Simonds\u00a0WF (2010) Clinical and molecular genetics of parathyroid neoplasms. Best Pract Res Clin Endocrinol Metab 24:491\u2013502","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"996_CR7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S0140-6736(17)31430-7","volume":"391","author":"JP Bilezikian","year":"2018","unstructured":"Bilezikian\u00a0JP, Bandeira\u00a0L, Khan\u00a0A, Cusano\u00a0NE (2018) Hyperparathyroidism. Lancet 391:168\u2013178","journal-title":"Lancet"},{"key":"996_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrendo.2017.104","volume":"14","author":"MD Walker","year":"2018","unstructured":"Walker\u00a0MD, Silverberg\u00a0SJ (2018) Primary hyperparathyroidism. Nat Rev Endocrinol 14:115\u2013125","journal-title":"Nat Rev Endocrinol"},{"key":"996_CR9","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1210\/jc.2013-1300","volume":"98","author":"NE Cusano","year":"2013","unstructured":"Cusano\u00a0NE, Maalouf\u00a0NM, Wang\u00a0PY, Zhang\u00a0C, Cremers\u00a0SC, Haney\u00a0EM, Bauer\u00a0DC, Orwoll\u00a0ES, Bilezikian\u00a0JP (2013) Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J\u00a0Clin Endocrinol Metab 98:2734\u20132741","journal-title":"J Clin Endocrinol Metab"},{"key":"996_CR10","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1210\/jc.2014-1413","volume":"99","author":"JP Bilezikian","year":"2014","unstructured":"Bilezikian\u00a0JP, Brandi\u00a0ML, Eastell\u00a0R, Silverberg\u00a0SJ, Udelsman\u00a0R, Marcocci\u00a0C, Potts\u00a0JT Jr. (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. J\u00a0Clin Endocrinol Metab 99:3561\u20133569","journal-title":"J Clin Endocrinol Metab"},{"key":"996_CR11","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1210\/jc.2008-2574","volume":"94","author":"MD Walker","year":"2009","unstructured":"Walker\u00a0MD, McMahon\u00a0DJ, Inabnet\u00a0WB, Lazar\u00a0RM, Brown\u00a0I, Vardy\u00a0S, Cosman\u00a0F, Silverberg\u00a0SJ (2009) Neuropsychological features in primary hyperparathyroidism: a\u00a0prospective study. J\u00a0Clin Endocrinol Metab 94:1951\u20131958","journal-title":"J Clin Endocrinol Metab"},{"key":"996_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ecl.2016.09.012","volume":"46","author":"KA Zanocco","year":"2017","unstructured":"Zanocco\u00a0KA, Yeh\u00a0MW (2017) Primary hyperparathyroidism: effects on bone health. Endocrinol Metab Clin North Am 46:87\u2013104","journal-title":"Endocrinol Metab Clin North Am"},{"key":"996_CR13","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1210\/jc.2014-3708","volume":"100","author":"C Cipriani","year":"2015","unstructured":"Cipriani\u00a0C, Biamonte\u00a0F, Costa\u00a0AG, Zhang\u00a0C, Biondi\u00a0P, Diacinti\u00a0D, Pepe\u00a0J, Piemonte\u00a0S, Scillitani\u00a0A, Minisola\u00a0S, Bilezikian\u00a0JP (2015) Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology. J\u00a0Clin Endocrinol Metab 100:1309\u20131315","journal-title":"J Clin Endocrinol Metab"},{"key":"996_CR14","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1210\/jc.2016-1513","volume":"101","author":"E Castellano","year":"2016","unstructured":"Castellano\u00a0E, Attanasio\u00a0R, Gianotti\u00a0L, Cesario\u00a0F, Tassone\u00a0F, Borretta\u00a0G (2016) Forearm DXA increases the rate of patients with asymptomatic primary hyperparathyroidism meeting surgical criteria. J\u00a0Clin Endocrinol Metab 101:2728\u20132732","journal-title":"J Clin Endocrinol Metab"},{"key":"996_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1530\/EJE-13-0305","volume":"169","author":"C Eller-Vainicher","year":"2013","unstructured":"Eller-Vainicher\u00a0C, Filopanti\u00a0M, Palmieri\u00a0S, Ulivieri\u00a0FM, Morelli\u00a0V, Zhukouskaya\u00a0VV, Cairoli\u00a0E, Pino\u00a0R, Naccarato\u00a0A, Verga\u00a0U, Scillitani\u00a0A, Beck-Peccoz\u00a0P, Chiodini\u00a0I (2013) Bone quality, as measured by trabecular bone score, in patients with primary hyperparathyroidism. Eur J Endocrinol 169:155\u2013162","journal-title":"Eur J Endocrinol"},{"key":"996_CR16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bone.2012.11.041","volume":"53","author":"E Romagnoli","year":"2013","unstructured":"Romagnoli\u00a0E, Cipriani\u00a0C, Nofroni\u00a0I, Castro\u00a0C, Angelozzi\u00a0M, Scarpiello\u00a0A, Pepe\u00a0J, Diacinti\u00a0D, Piemonte\u00a0S, Carnevale\u00a0V, Minisola\u00a0S (2013) \u201cTrabecular Bone Score\u201d (TBS): an indirect measure of bone micro-architecture in postmenopausal patients with primary hyperparathyroidism. Bone 53:154\u2013159","journal-title":"Bone"},{"key":"996_CR17","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s12020-020-02401-6","volume":"69","author":"D Miyaoka","year":"2020","unstructured":"Miyaoka\u00a0D, Imanishi\u00a0Y, Kato\u00a0E, Toi\u00a0N, Nagata\u00a0Y, Kurajoh\u00a0M, Yamada\u00a0S, Inaba\u00a0M, Emoto\u00a0M (2020) Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism. Endocrine 69:642\u2013649","journal-title":"Endocrine"},{"key":"996_CR18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/bju.14072","volume":"121","author":"GS Marchini","year":"2018","unstructured":"Marchini\u00a0GS, Faria\u00a0KVM, Torricelli\u00a0FCM, Monga\u00a0M, Srougi\u00a0M, Nahas\u00a0WC, Mazzucchi\u00a0E (2018) Sporadic primary hyperparathyroidism and stone disease: a\u00a0comprehensive metabolic evaluation before and after parathyroidectomy. BJU Int 121:281\u2013288","journal-title":"BJU Int"},{"key":"996_CR19","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1210\/jc.2018-00923","volume":"103","author":"H Ejlsmark-Svensson","year":"2018","unstructured":"Ejlsmark-Svensson\u00a0H, Bislev\u00a0LS, Rolighed\u00a0L, Sikjaer\u00a0T, Rejnmark\u00a0L (2018) Predictors of renal function and calcifications in primary hyperparathyroidism: a nested case-control study. J\u00a0Clin Endocrinol Metab 103:3574\u20133583","journal-title":"J Clin Endocrinol Metab"},{"key":"996_CR20","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.4158\/EP14074.OR","volume":"20","author":"S Cassibba","year":"2014","unstructured":"Cassibba\u00a0S, Pellegrino\u00a0M, Gianotti\u00a0L, Baffoni\u00a0C, Baralis\u00a0E, Attanasio\u00a0R, Guarnieri\u00a0A, Borretta\u00a0G, Tassone\u00a0F (2014) Silent renal stones in primary hyperparathyroidism: prevalence and clinical features. Endocr Pract 20:1137\u20131142","journal-title":"Endocr Pract"},{"key":"996_CR21","doi-asserted-by":"publisher","first-page":"908","DOI":"10.2214\/AJR.07.3160","volume":"191","author":"JM Suh","year":"2008","unstructured":"Suh\u00a0JM, Cronan\u00a0JJ, Monchik\u00a0JM (2008) Primary hyperparathyroidism: is there an increased prevalence of renal stone disease? AJR Am J Roentgenol 191:908\u2013911","journal-title":"AJR Am J Roentgenol"},{"key":"996_CR22","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1210\/jc.2011-0569","volume":"96","author":"L Rejnmark","year":"2011","unstructured":"Rejnmark\u00a0L, Vestergaard\u00a0P, Mosekilde\u00a0L (2011) Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J\u00a0Clin Endocrinol Metab 96:2377\u20132385","journal-title":"J Clin Endocrinol Metab"},{"key":"996_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/RLU.0000000000001941","volume":"43","author":"Z Cheng","year":"2018","unstructured":"Cheng\u00a0Z, Zou\u00a0S, Peng\u00a0D, Zhang\u00a0G, Zhu\u00a0X (2018) Prognostic value of 99mTc-sestamibi parathyroid scintigraphy in predicting future surgical eligibility in patients with asymptomatic primary hyperparathyroidism. Clin Nucl Med 43:151\u2013154","journal-title":"Clin Nucl Med"},{"key":"996_CR24","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1210\/jc.2007-1215","volume":"93","author":"MR Rubin","year":"2008","unstructured":"Rubin\u00a0MR, Bilezikian\u00a0JP, McMahon\u00a0DJ, Jacobs\u00a0T, Shane\u00a0E, Siris\u00a0E, Udesky\u00a0J, Silverberg\u00a0SJ (2008) The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15\u00a0years. J\u00a0Clin Endocrinol Metab 93:3462\u20133470","journal-title":"J Clin Endocrinol Metab"},{"key":"996_CR25","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1210\/jc.2014-3441","volume":"100","author":"K Lundstam","year":"2015","unstructured":"Lundstam\u00a0K, Heck\u00a0A, Mollerup\u00a0C, Godang\u00a0K, Baranowski\u00a0M, Pernow\u00a0Y, Varhaug\u00a0JE, Hessman\u00a0O, Rosen\u00a0T, Nordenstrom\u00a0J, Jansson\u00a0S, Hellstrom\u00a0M, Bollerslev\u00a0J, Group\u00a0SS (2015) Effects of parathyroidectomy versus observation on the development of vertebral fractures in mild primary hyperparathyroidism. J\u00a0Clin Endocrinol Metab 100:1359\u20131367","journal-title":"J Clin Endocrinol Metab"},{"key":"996_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.4199","volume":"36","author":"M Pretorius","year":"2021","unstructured":"Pretorius\u00a0M, Lundstam\u00a0K, Hellstrom\u00a0M, Fagerland\u00a0MW, Godang\u00a0K, Mollerup\u00a0C, Fougner\u00a0SL, Pernow\u00a0Y, Aas\u00a0T, Hessman\u00a0O, Rosen\u00a0T, Nordenstrom\u00a0J, Jansson\u00a0S, Heck\u00a0A, Bollerslev\u00a0J (2021) Effects of parathyroidectomy on quality of life: 10 years of data from a\u00a0prospective randomized controlled trial on primary hyperparathyroidism (the SIPH-study). J\u00a0Bone Miner Res 36:3\u201311","journal-title":"J Bone Miner Res"},{"key":"996_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000491035","volume":"51","author":"BL Clarke","year":"2019","unstructured":"Clarke\u00a0BL (2019) Asymptomatic primary hyperparathyroidism. Front Horm Res 51:13\u201322","journal-title":"Front Horm Res"},{"key":"996_CR28","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1001\/jamasurg.2017.1721","volume":"152","author":"AE Stephen","year":"2017","unstructured":"Stephen\u00a0AE, Mannstadt\u00a0M, Hodin\u00a0RA (2017) Indications for surgical management of hyperparathyroidism: a review. JAMA Surg 152:878\u2013882","journal-title":"JAMA Surg"},{"key":"996_CR29","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1002\/jbmr.3177","volume":"32","author":"K Lundstam","year":"2017","unstructured":"Lundstam\u00a0K, Heck\u00a0A, Godang\u00a0K, Mollerup\u00a0C, Baranowski\u00a0M, Pernow\u00a0Y, Aas\u00a0T, Hessman\u00a0O, Rosen\u00a0T, Nordenstrom\u00a0J, Jansson\u00a0S, Hellstrom\u00a0M, Bollerslev\u00a0J, SIPH Study Group (2017) Effect of surgery versus observation: skeletal 5\u2011year outcomes in a\u00a0randomized trial of patients with primary HPT (the SIPH study). J\u00a0Bone Miner Res 32:1907\u20131914","journal-title":"J Bone Miner Res"},{"key":"996_CR30","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1002\/jbmr.3461","volume":"33","author":"H Ejlsmark-Svensson","year":"2018","unstructured":"Ejlsmark-Svensson\u00a0H, Bislev\u00a0LS, Lajlev\u00a0S, Harslof\u00a0T, Rolighed\u00a0L, Sikjaer\u00a0T, Rejnmark\u00a0L (2018) Prevalence and risk of vertebral fractures in primary hyperparathyroidism: a nested case-control study. J\u00a0Bone Miner Res 33:1657\u20131664","journal-title":"J Bone Miner Res"},{"key":"996_CR31","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1177\/000313481708300326","volume":"83","author":"A Polistena","year":"2017","unstructured":"Polistena\u00a0A, Lucchini\u00a0R, Monacelli\u00a0M, Triola\u00a0R, Avenia\u00a0S, Barillaro\u00a0I, Johnson\u00a0LB, Sanguinetti\u00a0A, Avenia\u00a0N (2017) Current indications for surgical treatment of primary hyperparathyroidism in the elderly. Am Surg 83:296\u2013302","journal-title":"Am Surg"},{"key":"996_CR32","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jss.2011.03.014","volume":"170","author":"DC Thomas","year":"2011","unstructured":"Thomas\u00a0DC, Roman\u00a0SA, Sosa\u00a0JA (2011) Parathyroidectomy in the elderly: analysis of 7313 patients. J\u00a0Surg Res 170:240\u2013246","journal-title":"J Surg Res"},{"key":"996_CR33","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1097\/SLA.0000000000000812","volume":"261","author":"AG Abdulla","year":"2015","unstructured":"Abdulla\u00a0AG, Ituarte\u00a0PH, Harari\u00a0A, Wu\u00a0JX, Yeh\u00a0MW (2015) Trends in the frequency and quality of parathyroid surgery: analysis of 17,082 cases over 10\u00a0years. Ann Surg 261:746\u2013750","journal-title":"Ann Surg"},{"key":"996_CR34","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.surg.2007.09.003","volume":"142","author":"AI Stavrakis","year":"2007","unstructured":"Stavrakis\u00a0AI, Ituarte\u00a0PH, Ko\u00a0CY, Yeh\u00a0MW (2007) Surgeon volume as a\u00a0predictor of outcomes in inpatient and outpatient endocrine surgery. Surgery 142:887\u2013899 (discussion 887\u2013899)","journal-title":"Surgery"},{"key":"996_CR35","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/01.sla.0000234899.93328.30","volume":"244","author":"R Udelsman","year":"2006","unstructured":"Udelsman\u00a0R, Donovan\u00a0PI (2006) Remedial parathyroid surgery: changing trends in 130 consecutive cases. Ann Surg 244:471\u2013479","journal-title":"Ann Surg"},{"key":"996_CR36","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/jamasurg.2016.2310","volume":"151","author":"SM Wilhelm","year":"2016","unstructured":"Wilhelm\u00a0SM, Wang\u00a0TS, Ruan\u00a0DT, Lee\u00a0JA, Asa\u00a0SL, Duh\u00a0QY, Doherty\u00a0GM, Herrera\u00a0MF, Pasieka\u00a0JL, Perrier\u00a0ND, Silverberg\u00a0SJ, Solorzano\u00a0CC, Sturgeon\u00a0C, Tublin\u00a0ME, Udelsman\u00a0R, Carty\u00a0SE (2016) The American association of endocrine surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 151:959\u2013968","journal-title":"JAMA Surg"},{"key":"996_CR37","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s12149-020-01507-1","volume":"34","author":"L Evangelista","year":"2020","unstructured":"Evangelista\u00a0L, Ravelli\u00a0I, Magnani\u00a0F, Iacobone\u00a0M, Giraudo\u00a0C, Camozzi\u00a0V, Spimpolo\u00a0A, Cecchin\u00a0D (2020) (18)F-choline PET\/CT and PET\/MRI in primary and recurrent hyperparathyroidism: a\u00a0systematic review of the literature. Ann Nucl Med 34:601\u2013619","journal-title":"Ann Nucl Med"},{"key":"996_CR38","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s00259-018-4147-4","volume":"46","author":"A Piccardo","year":"2019","unstructured":"Piccardo\u00a0A, Trimboli\u00a0P, Rutigliani\u00a0M, Puntoni\u00a0M, Foppiani\u00a0L, Bacigalupo\u00a0L, Crescenzi\u00a0A, Bottoni\u00a0G, Treglia\u00a0G, Paparo\u00a0F, Del Monte\u00a0P, Lanata\u00a0M, Paone\u00a0G, Ferrarazzo\u00a0G, Catrambone\u00a0U, Arlandini\u00a0A, Ceriani\u00a0L, Cabria\u00a0M, Giovanella\u00a0L (2019) Additional value of integrated (18)F-choline PET\/4D contrast-enhanced CT in the localization of hyperfunctioning parathyroid glands and correlation with molecular profile. Eur J Nucl Med Mol Imaging 46:766\u2013775","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"996_CR39","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s00268-011-1068-9","volume":"35","author":"JM Schreinemakers","year":"2011","unstructured":"Schreinemakers\u00a0JM, Pieterman\u00a0CR, Scholten\u00a0A, Vriens\u00a0MR, Valk\u00a0GD, Rinkes\u00a0IH (2011) The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a\u00a0systematic review. World J Surg 35:1993\u20132005","journal-title":"World J Surg"},{"key":"996_CR40","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1210\/jc.2004-0028","volume":"89","author":"DS Rao","year":"2004","unstructured":"Rao\u00a0DS, Phillips\u00a0ER, Divine\u00a0GW, Talpos\u00a0GB (2004) Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J\u00a0Clin Endocrinol Metab 89:5415\u20135422","journal-title":"J Clin Endocrinol Metab"},{"key":"996_CR41","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJM199910213411701","volume":"341","author":"SJ Silverberg","year":"1999","unstructured":"Silverberg\u00a0SJ, Shane\u00a0E, Jacobs\u00a0TP, Siris\u00a0E, Bilezikian\u00a0JP (1999) A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N\u00a0Engl J Med 341:1249\u20131255","journal-title":"N Engl J Med"},{"key":"996_CR42","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1210\/jc.2006-1836","volume":"92","author":"J Bollerslev","year":"2007","unstructured":"Bollerslev\u00a0J, Jansson\u00a0S, Mollerup\u00a0CL, Nordenstrom\u00a0J, Lundgren\u00a0E, Torring\u00a0O, Varhaug\u00a0JE, Baranowski\u00a0M, Aanderud\u00a0S, Franco\u00a0C, Freyschuss\u00a0B, Isaksen\u00a0GA, Ueland\u00a0T, Rosen\u00a0T (2007) Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a\u00a0prospective, randomized trial. J\u00a0Clin Endocrinol Metab 92:1687\u20131692","journal-title":"J Clin Endocrinol Metab"},{"key":"996_CR43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00423-012-1026-5","volume":"398","author":"L Rolighed","year":"2013","unstructured":"Rolighed\u00a0L, Vestergaard\u00a0P, Heickendorff\u00a0L, Sikjaer\u00a0T, Rejnmark\u00a0L, Mosekilde\u00a0L, Christiansen\u00a0P (2013) BMD improvements after operation for primary hyperparathyroidism. Langenbecks Arch Surg 398:113\u2013120","journal-title":"Langenbecks Arch Surg"},{"key":"996_CR44","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1136\/bmj.325.7368.807","volume":"325","author":"CL Mollerup","year":"2002","unstructured":"Mollerup\u00a0CL, Vestergaard\u00a0P, Frokjaer\u00a0VG, Mosekilde\u00a0L, Christiansen\u00a0P, Blichert-Toft\u00a0M (2002) Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. BMJ 325:807","journal-title":"BMJ"},{"key":"996_CR45","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1210\/jc.2014-1417","volume":"99","author":"C Marcocci","year":"2014","unstructured":"Marcocci\u00a0C, Bollerslev\u00a0J, Khan\u00a0AA, Shoback\u00a0DM (2014) Medical management of primary hyperparathyroidism: proceedings of the fourth international workshop on the management of asymptomatic primary hyperparathyroidism. J\u00a0Clin Endocrinol Metab 99:3607\u20133618","journal-title":"J Clin Endocrinol Metab"},{"key":"996_CR46","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1055\/s-0043-105588","volume":"142","author":"H Siggelkow","year":"2017","unstructured":"Siggelkow\u00a0H (2017) Recent findings on primary hyperparathyroidism. Dtsch Med Wochenschr 142:790\u2013793","journal-title":"Dtsch Med Wochenschr"},{"key":"996_CR47","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1210\/jc.2013-3978","volume":"99","author":"L Rolighed","year":"2014","unstructured":"Rolighed\u00a0L, Rejnmark\u00a0L, Sikjaer\u00a0T, Heickendorff\u00a0L, Vestergaard\u00a0P, Mosekilde\u00a0L, Christiansen\u00a0P (2014) Vitamin D treatment in primary hyperparathyroidism: a\u00a0randomized placebo controlled trial. J\u00a0Clin Endocrinol Metab 99:1072\u20131080","journal-title":"J Clin Endocrinol Metab"},{"key":"996_CR48","doi-asserted-by":"publisher","first-page":"e6390","DOI":"10.1136\/bmj.e6390","volume":"345","author":"JM Paik","year":"2012","unstructured":"Paik\u00a0JM, Curhan\u00a0GC, Taylor\u00a0EN (2012) Calcium intake and risk of primary hyperparathyroidism in women: prospective cohort study. BMJ 345:e6390","journal-title":"BMJ"},{"key":"996_CR49","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0002-9343(97)00053-3","volume":"102","author":"FG Locker","year":"1997","unstructured":"Locker\u00a0FG, Silverberg\u00a0SJ, Bilezikian\u00a0JP (1997) Optimal dietary calcium intake in primary hyperparathyroidism. Am J Med 102:543\u2013550","journal-title":"Am J Med"},{"key":"996_CR50","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1001\/archinte.160.14.2161","volume":"160","author":"BJ Orr-Walker","year":"2000","unstructured":"Orr-Walker\u00a0BJ, Evans\u00a0MC, Clearwater\u00a0JM, Horne\u00a0A, Grey\u00a0AB, Reid\u00a0IR (2000) Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women. Arch Intern Med 160:2161\u20132166","journal-title":"Arch Intern Med"},{"key":"996_CR51","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s00198-014-3000-2","volume":"26","author":"R Cesareo","year":"2015","unstructured":"Cesareo\u00a0R, Di Stasio\u00a0E, Vescini\u00a0F, Campagna\u00a0G, Cianni\u00a0R, Pasqualini\u00a0V, Romitelli\u00a0F, Grimaldi\u00a0F, Manfrini\u00a0S, Palermo\u00a0A (2015) Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. Osteoporos Int 26:1295\u20131302","journal-title":"Osteoporos Int"},{"key":"996_CR52","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1210\/jc.2002-020667","volume":"88","author":"MR Rubin","year":"2003","unstructured":"Rubin\u00a0MR, Lee\u00a0KH, McMahon\u00a0DJ, Silverberg\u00a0SJ (2003) Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J\u00a0Clin Endocrinol Metab 88:1174\u20131178","journal-title":"J Clin Endocrinol Metab"},{"key":"996_CR53","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.surg.2019.04.059","volume":"167","author":"LE Orr","year":"2020","unstructured":"Orr\u00a0LE, Zhou\u00a0H, Zhu\u00a0CY, Haigh\u00a0PI, Adams\u00a0AL, Yeh\u00a0MW (2020) Skeletal effects of combined medical and surgical management of primary hyperparathyroidism. Surgery 167:144\u2013148","journal-title":"Surgery"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-00996-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-021-00996-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-00996-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T01:04:29Z","timestamp":1675040669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-021-00996-0"}},"subtitle":["Operieren oder beobachten?"],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["996"],"URL":"https:\/\/doi.org\/10.1007\/s00108-021-00996-0","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"assertion":[{"value":"16 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"H.\u00a0Siggelkow erhielt Vortragshonorare von den Firmen Amgen, Takeda, Alexion, UCB und Kyowa Kirin und Beraterhonorare von den Firmen Amgen, Takeda und UCB. K.\u00a0Gollisch gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autorinnen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}